PMDA — authorised 21 February 2020
- Marketing authorisation holder: Novartis Pharma K.K.
- Status: approved
🇯🇵 Sandimmune in Japan
PMDA authorised Sandimmune on 21 February 2020
Marketing authorisation
Sandimmune in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in Japan
Frequently asked questions
Is Sandimmune approved in Japan?
Yes. PMDA authorised it on 21 February 2020.
Who is the marketing authorisation holder for Sandimmune in Japan?
Novartis Pharma K.K. holds the Japanese marketing authorisation.